Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multicenter, First-in-human, Phase I Dose-escalation and Expansion Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of MRG001 in Patients With CD20-positive Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

Next Previous
Trial Profile

An Open-label, Multicenter, First-in-human, Phase I Dose-escalation and Expansion Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of MRG001 in Patients With CD20-positive Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MRG 001 Miracogen (Primary) ; Lenalidomide
  • Indications B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Miracogen

Most Recent Events

  • 16 Dec 2021 New trial record
  • 14 Dec 2021 Results (n=21; From June 25, 2019 to May 31, 2021) assessing the safety, tolerability, pharmacokinetics and preliminary antitumor activity in patients with CD20-positive relapsed or refractory B-cell non-hodgkin lymphoma, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top